Targeting PLCG2 Suppresses Tumor Progression, Orchestrates the Tumor Immune Microenvironment and Potentiates Immune Checkpoint Blockade Therapy for Colorectal Cancer
Xueliang Zhou, Joshua Lin, Yanfei Shao, Huang Zheng, Yi Yang, Shuchun Li, Xiaodong Fan, Hiju Hong, Zhihai Mao, Pei Xue, Sen Zhang, Jun Sun
Abstract
In summary, we have identified for the first time that PLCG2 could be considered a precise biomarker and promising therapeutic target for predicting CRC prognosis, optimizing individualized treatment, reversing CRC immune escape, and overcoming resistance to ICB therapy.
Topics & Concepts
BlockadeImmune checkpointImmune systemTumor microenvironmentCancer researchColorectal cancerCancerMedicineTumor progressionImmunologyImmunotherapyBiologyInternal medicineReceptorCancer Immunotherapy and BiomarkersFerroptosis and cancer prognosisCancer Mechanisms and Therapy